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To establish whether 4-nitroquinoline N-oxide-induced carcinogenesis mirrors the hetero-
geneity of human oral squamous cell carcinoma (OSCC), we have performed genomic
analysis of mouse tongue lesions. The mutational signatures of human and mouse OSCC
overlap extensively. Mutational burden is higher in moderate dysplasias and invasive SCCs
than in hyperplasias and mild dysplasias, although mutations in p53, Notch1 and Fat1 occur in
early lesions. Laminin-α3 mutations are associated with tumour invasiveness and Notch1
mutant tumours have an increased immune infiltrate. Computational modelling of clonal
dynamics indicates that high genetic heterogeneity may be a feature of those mild dysplasias
that are likely to progress to more aggressive tumours. These studies provide a foundation for
exploring OSCC evolution, heterogeneity and progression.
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Oral squamous cell carcinoma (OSCC), a subset of headand neck cancer, accounts for 355,000 new cancer casesannually worldwide1 and has a 5-year survival rate of
only 50%2. Current approaches to analysing the genetic hetero-
geneity of human head and neck cancer focus primarily on the
genetic lesions in frank tumours3–7. Recent whole-exome sequen-
cing3,4,8 has shown that most tumours have inactivating muta-
tions in Tp53, while mutations in Notch1, Fat1, Pik3ca and Casp8
are also frequent3,8. In addition to genetic heterogeneity, sig-
nificant inter-tumour heterogeneity is observed by histopathol-
ogy, reflecting the tumour site of origin, proliferation and
differentiation, depth of invasion and degree of inflammation9.
There is also evidence of field cancerisation, whereby tumours
develop within large pre-neoplastic regions (fields) of clonally
related cells10.
Epithelial cells can be readily cultured from resected tumours
and retain the range of mutations found in the original biopsy11,12.
However, in vitro experimental models are unable to capture
malignant transformation of early stage lesions and human tumour
xenografts cannot mimic the impact of a functional immune sys-
tem on tumour progression. To overcome the limitations of cur-
rent approaches to studying head and neck cancer, we have focused
on an autologous mouse model of OSCC that most commonly
affects the tongue. Tumours are induced by chronic oral admin-
istration of the water-soluble carcinogen 4-nitroquinoline-1-oxide
(4NQO)13–15 that mimics the alterations caused by tobacco
mutagens. As in human OSCC, invasive tumours are preceded by
epithelial hyperplasia and dysplasia. 4NQO forms DNA adducts,
causing substitution of adenosine for guanosine, and induces
intracellular oxidative stress resulting in mutations and DNA
strand breaks16. 4NQO is known to induce point mutations in
HRas with subsequent loss of heterozygosity17,18, upregulation of
EGFR19, p53 mutations20 and reduced expression of the cell cycle
inhibitor p1619. These effects are similar to the genetic alterations
induced by tobacco carcinogens19,21. However, while individual
molecular changes induced by 4NQO have been documented21–26,
a systematic genomic analysis has not been performed.
Here we provide a comprehensive genomic and clonal analysis of
4NQO-induced tumours at different stages of development and
correlate genetic changes with the tumour microenvironment. We
have uncovered the mutational landscape of 4NQO-induced tongue
squamous cell carcinoma (TSCC), identifying the recurrently
mutated genes and their time of onset. We have linked Lama3
mutations to tumour invasiveness and Notch1 mutations to an
increased immune cell infiltrate, and explored the clonal archi-
tecture of individual tumours. We conclude that the 4NQO carci-
nogenesis model captures many of the hallmarks of human OSCC.
Results
Whole-exome sequencing of 4NQO-induced TSCC. 4NQO was
delivered in the drinking water (100 µg/mL) of C57BL/l6 mice for
16 weeks. Mice were given normal drinking water for a further
10 weeks. We culled animals every 2 weeks during this period
(n= 75) (Fig. 1a). Lesions were identified and characterised
macroscopically, and formalin-fixed and paraffin-embedded
(FFPE) sections were analysed by microscopy (Fig. 1d, Supple-
mentary Fig. 1a, Supplementary Data 1 and 2). We performed
whole-exome sequencing (WES) of 69 4NQO-treated samples,
which were classified as follows: tongue that was histologically
normal but had been exposed to 4NQO (grade 1; n= 5),
hyperplasia (grade 2; n= 19), mild dysplasia (grade 3; n= 15),
moderate dysplasia (grade 4; n= 14), severe dysplasia (grade 5;
n= 3) and invasive SCC (grade 6; n= 13) (Fig. 1c, d). WES of
four tumours failed QC, and so mutational analysis was per-
formed on n= 65 tumours. Given the small number of severe
dysplasias and their histological similarity to moderate dysplasias,
we combined grades 4 and 5 for subsequent analysis. Most lesions
were found in the dorsal and ventral tongue, with a higher
number of advanced tumours (grades 4–6) in the dorsal tongue
(Fig. 1c).
For WES, we microdissected the epithelial compartment of
FFPE-fixed sections and extracted DNA (Supplementary Fig. 1a).
We performed WES using the HiSeq2000 Illumina platform
(average depth of 105x) of tongue 4NQO-treated samples, and
matched snap-frozen normal ear skin DNA from the same
animals. After somatic variant calling with CaVEMan (Cancer
Variants Through Expectation Maximisation)27, germline variant
filtering and exclusion of common variants (Supplementary
Fig. 1a), we identified a total of 515,212 mutations (Fig. 1e) and
663 Indels in the 65 samples. Higher mutation burden was
observed in moderate dysplasias and invasive SCCs than in
hyperplasias and mild dysplasias (Fig. 1e). Overall, C > T
mutations dominated the spectra, either in CpG or in other
dinucleotides. T > C and C > A mutations were also common
(Fig. 1f). The relative abundance of the different mutations did
not change significantly as lesions progressed from grade 1 to
grade 6 (Supplementary Fig. 1b).
The analysis was performed on FFPE samples because areas of
individual tumours could be micro-dissected with more accuracy
than in frozen sections, thereby reducing contamination of the
epithelial compartment with adjacent stroma. It has previously
been reported that formaldehyde fixation can result in artefacts;
these are of low allelic frequency (<5%) and share a “C > T”
mutational signature resulting from cytosine deamination28,29. To
take into account these potential artefacts, we used an effective
filtering strategy with associated empirical false-discovery estimates
in our analysis pipeline; we performed rigorous quality control
on extracted DNA and assessed sequence data quality, read
alignments, library complexity, raw error rate, and consensus base
calls. In addition, we used samples that were less than 6 months old
and confirmed that they did not have the typical increase in C > T
transitions observed in archival FFPE30,31 (Supplementary Fig. 1c).
Therefore analysis of the allelic frequencies of our FFPE samples
confirmed that they are unlikely to be artefacts of formalin
fixation31.
DNA from frozen sections of ear skin, taken prior to 4NQO
treatment, provided the controls for germline mutations in each
mouse. In addition, WES was performed on FFPE sections of
untreated tongues from two C57Bl/6N mice (samples MD5547b
and MD5548b).
Mutagenic processes generate characteristic point mutation rate
spectra (mutational signatures) that are identified as common
patterns based on counts of mutations and their sequence context.
We extracted 3 de novo mutational signatures from our samples,
indicated as Signatures A, B and C (Fig. 1g and Supplementary
Fig. 1d). Half of the more aggressive samples (grade 4–6) were
enriched in Signature C, while Signature A was enriched in grade
1–3 samples. We also analysed the similarity between each
mutational profile and the 30 recurrent base substitution patterns
that are archived in the Catalogue of Somatic Mutations in Cancer
(COSMIC)32 (Fig. 1h and Supplementary Fig. 1e, f). Moderate and
severe dysplasias and invasive SCCs (grades 4–6) showed an
enrichment of signatures related to advanced human OSCC. In
particular, these tumours presented a high similarity to Signatures
4, 18 and 29 (cosine of similarity > 0.90) (Fig. 1g). Signatures 4, 18
and 29 are observed specifically in human head and neck SCC,
oesophageal, stomach and gingiva-buccal oral SCCs and are
known to be associated with mutations due to tobacco use33.
Comparison of the de novo signatures with COSMIC signatures
revealed that de novo signature C correlates with COSMIC
signature 4 while de novo signature B with COSMIC signature 5
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(cosine of similarity of 0.917 and 0.871, respectively) (Supple-
mentary Fig. 1e).
Mutated genes in 4NQO-induced TSCCs. We next analysed all
the genes that were mutated in our samples and correlated the
mutated genes with the corresponding biological information,
including tumour grade, degree of differentiation and invasive-
ness, proliferation index and extent of immune cell infiltrate
(CD45+, CD3+ and CD68+ cells) (Fig. 2; Supplementary Figs. 2,
3 and 5a, d, Supplementary Data 1). A total of 14,003 genes had at
least one mutation in at least one of the samples analysed
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(Supplementary Data 2). Overall, the total number of single
nucleotide variants (SNVs) increased with increasing tumour
grade (Fig. 1e, Supplementary Fig. 3). However, a subset of
hyperplastic lesions had an increased number of SNVs, corre-
lating with the length of 4NQO treatment (treatment longer
>12 weeks, Fig. 2, Supplementary Fig. 3).
Among the top 100 mutated genes (Supplementary Fig. 2) were
several that are known to be mutated in human head and neck
SCC, including Trp53, Erbb4 and 4 genes of the Fat family. We
then focused on genes that are known to harbour bona fide driver
mutations in human TSCCs34 (see Methods and Supplementary
Data 3). From the mouse tongue recurrent mutated genes (all
SNVs, including missense, nonsense, ess-splice and indels), the
highest ranked genes included Trp53, Fat1, Syne2 and Notch1
(Fig. 2).
Fat1 was mutated in 30% of the tumours, particularly in
moderate and severe dysplasias and invasive SCC (Fig. 2). Loss of
Fat1 has been variously associated with improved or decreased
patient survival35,36 and gives a competitive advantage to OSCC
cells in culture12. Trp53 is a well-known tumour suppressor
gene37. In human head and neck SCC, the overall frequency of
Tp53 mutations is approximately 70%3,4,6 but the incidence in
TSCCs is lower at 38.3%34. Consistent with the human data, Tp53
was mutated in 30% of our samples and mutations were found in
more aggressive lesions (dysplasias and invasive SCC), suggesting
that this gene plays an important role in tumour progression.
Trp53 mutations were also found in hyperplastic lesions but
only in mice treated for a long period with 4NQO (Fig. 2,
Supplementary Fig. 3), supporting the observation that loss of p53
alone is not responsible for tumour initiation38. Syne2 and Notch1
were mutated in 23 and 9% of our samples, respectively and, like
Fat1 and Trp53, are frequently mutated in human head and neck
SCC3–7.
To detect additional cancer driver genes (i.e. genes under
positive selection in cancer), we used the dNdScv method to
calculate dN/dS ratio (the normalised ratio of non-synonymous to
synonymous mutations) for missense, nonsense and essential
splice mutations39. This revealed 35 genes under positive selection
(p-value <0.001) (Fig. 2, Supplementary Data 4). These data show
similarity between the recurrently mutated genes in human OSCC
and mouse OSCCs and identify additional possible driver genes
such as Chuk, a serine/threonine protein kinase that is involved in
nuclear factor κ-B (NF-κB) activation and functions as a tumour
suppressor by controlling turnover of cyclin D140,41. A previous
study has shown that genes involved in the NF-κB pathway,
including Chuk, are upregulated in skin SCCs42. In OSCC, Chuk
has been previously associated with ELAVL143, an RNA-binding
protein that stabilises the transcripts of many cancer-related
genes and is also a putative driver gene44 (Supplementary Data 4).
Kras, a gene within the RAS family involved in signal transduction
and cell cycle regulation, was also mutated in 12% of our samples
(Fig. 2).
Antibody labelling supported the identification of mutations in
two of the genes (Fig. 3a–d). Tumours that were mutant for
Lama3 had areas in which the protein was absent from the
basement membrane, consistent with a loss of function mutation
(Fig. 3a, b), leading to multifocal breaks of the epithelial-
mesenchymal boundary. Lama3 mutations were only observed in
moderate and severe dysplasias and invasive SCC (Fig. 3a,
Supplementary Fig. 2), suggesting that loss of Lama3 expression
may contribute to a more invasive phenotype45. Tumours
mutated in p53 exhibited enhanced staining with anti-p53 (Fig. 3c,
d) suggesting they had stabilising mutations in Trp53. To gain a
broader perspective on changes in the tumour ecosystem46, we
performed Gene Ontology (GO term) analysis based on the driver
genes we identified (Fig. 3c; Supplementary Data 5). In addition
to changes in the epithelial compartment (GO terms: morpho-
genesis, anatomical structure), GO term analysis predicted
alterations in cytokine-mediated signalling and immune infiltrate.
Highly mutated hyperplasias lack cancer driver gene muta-
tions. Although in general the number of SNVs increased with
increasing tumour grade (Fig. 2), we observed a subgroup of
hyperplastic lesions with a high number of SNVs. These corre-
sponded to lesions in tongues that had been treated with 4NQO
for prolonged periods (>10 weeks of 4NQO treatment) without
developing into aggressive tumours. Combining transcriptome
(RNAseq data from normal tongue23) and mutational analysis
(Fig. 4), we analysed the expression level (log CPM – Count Per
Million normalised read count) of genes mutated in these
hyperplastic lesions (Fig. 4a). We placed the genes into three
categories based on the average CPM values: (i) low expression
(log CPM < 4.5); (ii) medium expression (log CPM between
4.5–10); (iii) high expression (log CPM > 10). The number of
genes in each category is shown in Fig. 4b, c.
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway
analysis of genes with medium and high expression levels
(Fig. 4d) in both the hyperplasias and invasive SCC showed
significant enrichment in cancer associated pathways: “Focal
adhesion”, “Proteoglycans in cancer” and “Axon guidance” (genes
related to cell migration and apoptosis). Nevertheless, a minority
of genes mutated in hyperplastic lesions only (243 out of 1691)
were enriched in pathways related to cancer progression (“ECM-
receptor interaction”, “Calcium signalling”), whereas all the genes
mutated in invasive SCC and not in hyperplasias were enriched in
pathways associated with cancer47. These results suggest that the
reason why the hyperplasias with a high number of SNVs do not
Fig. 1 Mutational burden and signature of 4NQO-induced TSCCs. a Schematic of 4NQO tumorigenesis protocol. Mouse image obtained from Pixabay
(https://pixabay.com/service/terms/) and used in accordance with the terms of the Pixabay License. OSCCs were induced in C57BL/6 mice (n= 75) by
administration of 4NQO carcinogen in the drinking water of mice for 16 weeks. Harvesting of tumours was done every 2 weeks for a total of 26 weeks.
b Distribution of tumours on the tongue by grade. c Distribution of tumour grade according to the number of weeks of 4NQO treatment represented as
boxplots (the middle line is the median, the lower and upper hinges are the first and third quartiles, the upper whisker extends from the hinge to the largest
value no further than 1.5× inter-quartile range from the hinge and the lower whisker extends from the hinge to the smallest value at most 1.5× inter-quartile
range of the hinge. Data beyond the end of the whiskers are outliers that are plotted individually). d Histological heterogeneity of 4NQO-induced TSCCs.
Representative images of haematoxylin & eosin staining (H&E) of tongue lesions for each tumour grade: Grade 1 (normal 4NQO-treated, n= 5), Grade 2
(hyperplasia, n= 19), Grade 3 (mild dysplasia, n= 15), Grade 4 (moderate dysplasia, n= 14), Grade 5 (severe dysplasia, n= 3) and Grade 6 (invasive SCC,
n= 13). Scale bars 100 µm. e Differences in mutation burden by grade. Barplot depicts total SNVs per tumour grade (n= 65 biologically independent
samples, bar graphs represent mean ± SD, ****p < 0.0001, one-way ANOVA). f Mutational signature of all 4NQO-induced OSCCs (N= 515,212 mutations,
n= 65 samples, bar graphs represent mean ± SD over all samples). g De novo signatures. h Similarity heatmap featuring the contribution of known
COSMIC signatures calculated using MutationalPatterns (R package) for tumour grades 4, 5 and 6. Each number corresponds to the tumour reference:
tumour grade (1–6), tumour site (D, dorsal; L, lateral; V, ventral) and the tumour sequencing ID.
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Fig. 2 Data matrix showing mutational landscape of 4NQO-induced TSCCs compared with tumour ecology, including recurrent somatic mutations. The
top panel shows the key clinical parameters: colour coding indicates number of weeks of treatment, number of lesions per tongue, site of the sequenced
lesion (dorsal, ventral or lateral), diagnosis (tumour-grade), differentiation status, exophytic tumour (yes/no), invasive tumour (yes/no), proliferation
index, and immune-infiltrate index (CD45+ cells) (Supplementary Data 1 2 and 3). The middle and the bottom panels show the significantly mutated genes
(rows; tongue recurrently mutated genes and a subset of dNdS genes, respectively) coloured by the types of mutation. Samples (columns, n= 65) are
organised by diagnosis by increasing grade. Somatic mutations are presented according to the type of mutation (missense, nonsense, exonic splicing
silencer ‘Ess_Splice’, deletion or silent mutations; colours defined in key). All mutations are listed in Supplementary Data 3, 4 and 5. The distribution
between the types of somatic alterations for each gene is shown in the histogram (right). Percentages on the left represent the fraction of tumours
harbouring mutations in the corresponding gene.
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progress to invasive SCC is because the mutated genes are not
essential for tumour progression.
Correlation between mutational landscape and tumour ecol-
ogy. To determine whether the mutational landscape of indivi-
dual tumours correlated with tumour phenotype, we quantified
the immune cell infiltrate by labelling sections with antibodies
against CD45 (all immune cells), CD3 (T-cells) and CD68
(macrophages) and measured the proportion of proliferating cells
(EdU+) in all sequenced tumours (Fig. 5a–d; Supplementary
Fig. 4a, b, Supplementary Table 1 and Supplementary Data 1).
There was considerable heterogeneity within each grade and there
was no statistically significant difference between different grades.
We next performed linear regression analysis to compare
multiple biological parameters (linearMod, pvalue cut-off < 0.05)
(Supplementary Data 1) with the frequency of mutations and
Variant Allele Frequency (VAF) in individual genes (Fig. 5e;
Supplementary Fig. 4c, d, Supplementary Data 6). The total
number of mutant genes was significantly correlated with exofitic
tumours (i.e., moderate and severe dysplasias), aggressive lesions
(grades 4–6) and proliferation index (Supplementary Fig. 4d).
Although there was no significant difference in the number of
proliferative basal cells in different grades of lesion (Fig. 5d) there
was an increased abundance of proliferative Krt14+ cells above
the basal layer (Supplementary Fig. 4b). In addition, although
there was no significant difference in proliferation across all
tumour grades, there was a significant increase in SCC compared
to hyperplasias (p= 0.0262, Fig. 5d).
Lama3 mutations correlated with tumour grade (p= 0.00233),
total immune infiltrate (CD45+, p= 0.029824), exofitic tumour
growth (p= 0.05172) and tumour invasiveness (p= 0.02748)
(Fig. 5e, Supplementary Data 6). Mutations in Fat1 correlated
positively with proliferation (p= 0.04094) and inversely with
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Fig. 3 Expression of Lamininα3 and p53 in mutated tumours. a, c Representative images of immunostaining of Lamininα3 (a) and p53 (c) in normal tissue,
wild-type and mutated tumours. Arrowheads indicate areas with loss of Lamininα3 expression in mutated tumours (n= 6 lesions mutated for Lamininα3).
Samples were counterstained with nuclear dye DAPI (4′,6-diamidino-2-phenylindole) (a) or with haematoxylin (c). Dotted line delineates basement
membrane. Scale bars, 100 µm. b Quantification of the expression of Lamininα3 in the basement membrane (n= 3 normal samples with n= 7 regions of
interest (ROIs) quantified, n= 3 tumour Lama3 wt samples with n= 5 ROIs quantified, n= 4 tumour Lama3 mutated samples with n= 9 ROIs quantified).
d Quantification of p53 positive cells (n= 3 normal, 3 tumour p53 wt samples, 4 tumour p53 mutated samples). Bar graphs represent mean ± SD, **p≤
0.05, ***p≤ 0.001, p= 0.0014 for p53, p= 0.0010 for Lamininα3, one-way ANOVA, Kruskal–Wallis test. e Gene Ontology analysis of driver genes. Each
rectangle is a single cluster representative of GO categories (biological processes), joined together into three main categories (superclusters): cytokine-
mediated signalling pathway, morphogenesis of an epithelium and immune system process. Size of the rectangles is adjusted to reflect the frequency of the
GO term in the underlying GO analysis database.
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tumour grade35 (p= 0.00128) and exofitic tumour growth (p=
0.02702)(Fig. 5e). Trp53 mutations positively correlated with high
grade tumours (p= 0.05160) but no other parameters, while
Notch1 mutations correlated significantly with an increased total
immune cell infiltrate (CD45+, p= 0.00069), T-cell infiltrate (CD3+,
p= 0.02019) and high tumour grade (p= 0.01288)(Fig. 5e, Supple-
mentary Data 6). We validated these observations by confirming
that the tumours with Notch1 mutations had a higher stromal
CD45+ and CD3+ infiltrate than tumours that were wild type
for Notch1 (Fig. 5f–h). There was no correlation between Notch1
mutational status and macrophage infiltration (CD68+ cells)
(Fig. 5e).
Tumour clonal dynamics. The somatic mutation theory of
cancer invokes a clonal origin of tumours, with lesions arising
from sequential mutations in the progeny of a single cell48.
However, it is now apparent that genetically distinct clonal sub-
populations can co-exist within a single tumour for long periods
of time49–52. To investigate the clonal dynamics and architecture
of 4NQO-induced TSCCs, we first analysed mice treated with
4NQO that had more than one distinct lesion at the time of
harvest. In 8 mice analysed the lesions were at different stages of
progression, with hyperplasia, dysplasia and/or SCC on different
locations of the tongue (Supplementary Fig. 5). In 4 out of 8
animals, the different lesions had no common mutations and in 2
out of 8 there were ≤3 mutations in common. Of the remaining
two mice, only one had a significant number of mutations shared
between two lesions (n= 1189, Supplementary Fig. 5a). In this
mouse both lesions were located in close proximity in the dorsal
region of the tongue (Supplementary Fig. 5b, 2_D_MD5534c and
4_D_MD5534a). These observations suggest that lesions in dif-
ferent regions of the same tongue are not clonally related, except
when located in close proximity to one another.
We next assessed the clonality of mutations within individual
lesions using computational methods of clonal selection, analysing
the variant allele frequency (VAF) of each mutation53–55. A detailed
analysis of subclonality was precluded in most cases due to the low
median VAF (0.11). This may be due to low tumour purity or the
presence of multiple low frequency clones. In some of the higher-
grade lesions, we did however observe enrichment in the number of
clonal mutations (VAF > 0.25) together with an enrichment of high
frequency putative driver mutations (Fig. 6c, sample 6_L_MD5541,
invasive SCC; Fig. 6b, sample 4_V_MD5538A, moderate/severe
dysplasia). This may be due to the clonal expansion of a fitter clone
carrying multiple drivers.
There were other noticeable differences in VAF distributions
across samples that reflect the evolutionary history of different
lesions. Principally, some samples had a large number of clonal
mutations whereas other samples had very few (Fig. 6b, c). The
number of clonal mutations is a measure of the mutation burden
of the most recent common ancestor (MRCA) of the sampled
population. A high clonal mutation burden may therefore be the
result of a selective sweep of a fitter clone, the larger the mutation
burden the later the sweep and consequently the fitter the clone55.
Consistent with this hypothesis, when we compared tumour
grade with tumour clonal selection, most of the mild dysplasias
had few clonal mutations, while a subset of higher-grade tumours
presented patterns consistent with clonal mutations (Fig. 6c).
However, we observed that tumours bearing subclonal mutations
started to emerge as early as grade 3, mild dysplasia (Fig. 6c).
To broadly assess which mutated genes were present in each
clone, we annotated the mutated genes in each VAF peak. We
observed that in high-grade tumours bearing a clone, Notch1,
Fat1 and Syne2 mutations had a similar VAF (Fig. 6c), whereas in
lower grade lesions subclonal mutations in KRAS (Fig. 6b) and
Tp53 (Fig. 6c) were observed. We speculate that high genetic
heterogeneity may be a feature of those mild dysplasias that are
likely to progress to more aggressive tumours. Taken together,
these data shine light on the evolutionary dynamics of tumour
progression.
Discussion
We have found that the mutational spectrum of human OSCC is
faithfully recapitulated in 4NQO-induced mouse tumours,
including mutations in Trp53, Pik3ca, Notch1, Fat1, Lama3 and
Syne2. In addition, we provide a comprehensive analysis of the
genomic landscape of 4NQO carcinogenesis at different stages of
tumour development, from early hyperplasia to invasive SCC.
This provides insights that cannot be gained from end-point
analysis of malignant tumours.
By correlating the different biological parameters of individual
tumours with their mutational spectrum, we were able to show
that mutant Fat1 is associated with tumour grade and high
proliferation rate, while Trp53 correlates with tumour grade, and
Notch1 with immune infiltrate (Fig. 5e–h). Notch1 is known to
regulate the crosstalk between different cells in the tumour
microenvironment56. The tumour-promoting effect of Notch1
inactivation in the epithelia of the skin, oral cavity and oeso-
phagus is well established, and our data suggest that this is
mediated, at least in part, by triggering inflammation8,57–62. In
colorectal cancer, Notch1 signalling leads to highly penetrant
metastasis through control of inflammatory chemokine expres-
sion63. Furthermore, a recent report on human head and neck
SCC has shown how mutations in multiple genes converge on the
Notch signalling pathway, making NOTCH inactivation a hall-
mark of this cancer64.
The loss of Laminin-α3 (Lama3) in higher-grade tumours
(moderate dysplasia to invasive SCC) (Fig. 3a, c, Fig. 6a, Supple-
mentary Fig. 2) could be used as a marker to predict metastatic
behaviour. Our results provide grounds for optimism that in future
it may be possible to accurately predict mutational burden from
analysis of tumour histology, leading to new and earlier therapeutic
interventions. Since several of the mutant genes, such as Lama3 and
Trp53, are readily detected by antibody staining (Fig. 3a, b), it may
also be possible to map the ecology of individual tumours with
respect to the appearance of specific mutations.
Clonal architectures are prevalent across cancer types65 and it
is now apparent that genetically distinct clonal subpopulations
can co-exist within a single tumour for long periods of time49–51.
Passenger mutations that are phenotypically silent in normal
tissue can confer a growth advantage in the context of a tumour54
and increase invasiveness12,66. Understanding the dynamics of
cancer evolution can provide a quantitative measurement of
tumour heterogeneity from early stage-lesions to invasive SCCs.
By inferring tumour clonality from mutational burden it is pos-
sible to predict the evolutionary outcome of an early lesion52.
We detected the emergence of clonal organisation of TSCCs
from early stage lesions (mild dysplasia) to moderate/severe dys-
plasia and invasive SCC (Fig. 6). A subset of higher-grade tumours
presented patterns consistent with clonal mutations, consistent
with previous observations that clonal diversity encompasses the
genetic heterogeneity of more aggressive tumours. However, in
addition, heterogeneity was a feature of some mild dysplasias,
which we speculate are likely to progress. Their identification
could improve early interventional treatment strategies, since
genetic heterogeneity is likely to be one of the main causes for
treatment failure.
In summary, we have been able to integrate genetic and phe-
notypic heterogeneity46 within a mouse model of OSCC that
faithfully recapitulates many aspects of the human disease. We can
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now build on these studies to improve diagnosis and treatment of
human OSCC.
Methods
4NQO carcinogenesis. All animal procedures were subject to institutional ethical
review and were approved by the UK Home Office (in accordance with UK law,
Animals Scientific Procedures Act 1986) at King’s College London prior to com-
mencement. Mice from both genders were maintained on the C57BL/6 N genetic
background and were housed under a 12 hour light/12 hour dark cycle, at tem-
peratures of 20–24 °C with 45–65% humidity. 4NQO (Sigma, diluted to 100 µg/mL)
was administered in the drinking water. 4-NQO–containing water was prepared and
changed once a week for 16 weeks. After that period, mice were given drinking
water without 4NQO. Mice were maintained with regular mouse chow and water
(±4NQO) ad libitum. Once a week, 4NQO-treated mice were sedated with inhaled
isoflurane and the oral cavities were screened for lesions (hyperplasias, dysplasias
and SCCs). Mice were injected with 500 µg EdU (5-ethynyl-2’-deoxyuridine, Invi-
trogen) in PBS intraperitoneally 2 h before culling to assess proliferation. Sample
sizes were determined on the basis of prior power calculations.
Tumour harvesting and histology. Tongue tissues and lymph nodes were har-
vested at different time-points during 4NQO treatment. Ear skin was collected as
a control for sequencing, before the start of the 4NQO treatment. WES was also
performed on untreated tongues from C57BL/6 N mice following the same pro-
tocol (Supplementary Fig. 1) to provide germline DNA for the elimination of
single-nucleotide polymorphisms. For frozen sections, tissues were embedded in
OCT (optimal cutting temperature compound, VWR), sectioned and post-fixed in
4% paraformaldehyde/PBS pH 7.4 for 10 min before staining. For paraffin sections,
tongue samples were fixed with 10% neutral buffered formalin overnight before
paraffin embedding. The tissues were sectioned and stained with haematoxylin and
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eosin (H&E) by conventional methods. Images were acquired using a Hamamatsu
slide scanner and analysed using NanoZoomer software (Hamamatsu).
Histological classification. Tumour grading was assessed according to the pre-
sence of the following criteria: tumour cell crowding, degree of keratinisation,
exofitic or invasive growth, scattered mitotic figures and nuclear atypia67 (Sup-
plementary Table 1). All histology was called by a pathologist blinded to the study
groups and 4NQO treatment conditions.
Whole-exome sequencing. Tongue lesions and normal tissue were microdissected
from 20–25 FFPE sections of 5µm-thickness (Supplementary Fig. 1a). Matched
control ear samples were frozen prior to DNA extraction. DNA was extracted and
purified using the QIAamp DNA FFPE Tissue Kit (Qiagen) according to the
manufacturer’s recommendations. Exonic DNA was captured using the Agilent
whole exome capture kit (SureSelect Mouse All Exon). Captured material was
indexed and sequenced on the HiSeq2000 Illumina platform at the Wellcome Trust
Sanger Institute at an average depth of 105x. Raw pair end sequencing reads were
aligned with BWA-mem to the GRCm38 mouse reference genome68. Duplicated
reads were marked using biobambam69. The sequencing metrics of the individual
samples are summarised in Supplementary Data 2.
Somatic variant detection. Somatic variants were detected using CaVEMan, an
expectation maximisation–based somatic substitution detection algorithm27.
Candidate somatic variants were then filtered for quality and to remove known
mouse genome variations70. Single point mutations overlapping known structural
variants in any of the 17 mouse genomes were also removed due to high mis-
alignment rate in these regions. Small insertion and deletion (indel) detection was
performed using the cgp-pindel pipeline (v0.2.4w)71. Detected indels were then
filtered for quality, sequence coverage in both tumour and normal, strand bias and
for overlap with known simple repeats or indels in the in-house normal panel.
Validation of SNVs. All potential recurrent mutations underwent extensive
manual review using the Integrative Genomics Viewer72 (IGV v2.3) to exclude the
possibility that they represented germline SNPs and to ensure models were gen-
erated using high-confidence mutations.
Variant quality control for FFPE artefacts. Formalin fixation of tumour biopsies
can have a detrimental impact on DNA integrity and introduce C > T/G > A
sequencing artefacts, which are more frequently observed at a 0.01–0.10 mutant
allele fraction (MAF)31. To reduce the potential impact of these artefacts in our
FFPE samples, we tested for low allelic fraction mutations (mutant allele fraction
<0.10 and read depth <10) and removed them from the signature delineation
process.
Mutation spectra analysis. SNVs in all tumours were annotated by the 96 pos-
sible trinucleotide context substitutions (6 types of substitutions × 4 possible
flanking 5′ bases × 4 possible flanking 3′ bases) and summed in each tumour.
Mutational Pattern analysis (Fig. 1 and Supplementary Fig. 1) was performed using
the R package MutationalPatterns73. Vcf files were used as input and the base
substitutions were retrieved using the mutations_from_vcf() function. Three new de
novo signatures were extracted using the extract_signatures() function. To find
optimal contribution of known signatures, 30 human cancer signatures (COSMIC
signatures as defined in Alexandrov et al.32) were downloaded from the website
and the similarity between the mutational profiles of our samples and COSMIC
signatures was calculated using the cos_sim_matrix() and visualised using the
plot_cosine_heatmap() functions.
Similarity between mouse SCC and human SCC data. A list of 465 human genes
from Vettore et al.34 was used to compare the human versus mouse mutational
landscape of OTSCC. Genes were divided into four classes: (i) Tongue WES –
Recurrence; (ii) Tongue WES – Non-recurrence; (iii) Cancer genes, and (iv) Genes
from related studies (Supplementary Data 3).
Analysis of positively selected driver genes in 4NQO samples. Driver genes
were selected using the dNdScv algorithm39 implemented in the dNdScv R package,
a suite of maximum-likelihood dN/dS methods designed to quantify selection in
cancer and somatic evolution. The algorithm was applied to the list of detected
mutations in each sample and was used quantify dN/dS ratios for missense,
nonsense and essential splice mutations using trinucleotide context-dependent
substitution models to avoid common mutation biases affecting dN/dS39,74. The
necessary reference file for the mouse genome was generated and used as input.
The algorithm outputs two tables (Supplementary Data 4): the first table contains
all the genes with p values <0.01 (obtained by Likelihood-Ratio Tests)39 while the
second one is an annotated table of coding mutations.
Gene Ontology analysis of driver genes. The list of genes detected with dNdScv
algorithm was used as input for a Gene Ontology (GO) analysis using the Gorilla
(Gene Ontology enRIchment anaLysis and visualisation tool) online software
(http://cbl-gorilla.cs.technion.ac.il/). Results for Biological Processes were selected
and a p-value threshold of 0.01 applied. The visualization was obtained using the
REViGO online tool (http://revigo.irb.hr/).
KEGG pathway analysis of mutated gene expression. Expression data from
Tang et al. (GSE54246) was downloaded from the iDEP-reads database23 and row
counts were normalised to Count Per Millions (CPM) using a custom R script
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54246). 5 samples of
normal mouse tongues were used to analyse significantly altered pathways in genes
mutated in hyperplastic lesions vs invasive SCC lesions. Genes were classified into 4
categories according to expression values: (i) no expression, (ii) low expression (logCPM
<4.5), (iii) medium expression (logCPM 4.5 < >10), (iv) high expression (logCPM>10).
We performed Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis
of the medium and highly expressed genes using ShinyGO software75, selecting only the
top 10 enriched pathways with a P-value cutoff (FDR) of 0.05.
Tumour clonal analysis from bulk sequencing data. To interrogate the clonality
of the samples we calculated the variant allele frequency (VAF) of each mutation,
only considering mutations with a depth >20.
Generation of plots. All plots were created using the statistical computing lan-
guage R (http://www.R-project.org/). The ComplexHeatmap R Package (https://
jokergoo.github.io/ComplexHeatmap-reference/book/) was used to create the plots
in Fig. 2 and Supplementary Fig. 2 with the oncoPrint() and HeatmapAnnotation()
functions to generate the heatmap and the annotation bars respectively. All other
plots were made using the ggplot2 package (http://ggplot2.org/).
Immunofluorescence staining. Frozen sections were fixed in 2% paraformalde-
hyde/PBS pH 7.4 and blocked with 10% foetal bovine serum, 2% BSA, 0.02% fish
skin gelatin, 0.05% TritonX100 (Sigma) and 0.05% Tween (Sigma) in PBS for 1 h at
room temperature. Paraffin sections were subjected to heat-mediated antigen
retrieval (citrate buffer, pH6) prior to blocking. Primary antibodies were incubated
overnight at 4 °C, followed by 1 h incubation at room temperature in secondary
antibodies.
The following primary antibodies were used: rabbit anti-Krt14 (Covance, PRB-
155P, 1/5000), chicken anti-krt14 (Biolegend, clone Poly9060, 1/5000), rat anti-
CD45 (BD Pharmingen clone 30-F11, 1/200), rabbit anti-CD3 (abcam clone SP7, 1/
150), rat anti-CD68 (abcam, clone FA-11, 1/75), polyclonal rabbit anti-laminin-α3
(gift from Matthew Caley, clone R14, 1/200), rabbit anti-p53 (Leica Biosystems,
Novocastra NCL-L-p53-CM5p, 1/500). For immunofluorescence, the following
conjugated secondary antibodies were used: AlexaFluor488 goat anti-chicken
(#A11039), AlexaFluor555 donkey anti-rabbit (#A31572), AlexaFluor594 goat anti-
rat (#A11007), AlexaFluor647 chicken anti-rat (#A21472) (all Invitrogen,
purchased from ThermoFisher Scientific, 1/300). EdU staining was performed with
a Click-it EdU imaging kit (Life Technologies) according to the manufacturer’s
recommendations. DAPI (Life Technologies) was used as a nuclear counterstain.
Slides were mounted using ProLong Gold anti-fade reagent (Life Technologies).
Images were acquired with a Nikon A1 Upright and with a Leica SP8 Confocal
microscope. Images were analysed using ICY software76.
Rabbit anti-p53 immunohistochemistry staining was detected using a standard
DAB kit (Imm PRESS™ Duet Double Staining Polymer Kit, MP-7714, anti-rabbit
IgG Peroxidase ImmPACT™ DAB EqV and ImmPACT™ DAB Peroxidase Substrate
Kit SK-4105, Vector Laboratories). Nuclei were counterstained with haematoxylin.
Slides were mounted using DPX mounting medium. Images were acquired using
a Hamamatsu Slide Scanner at 40x amplification and analysed using NanoZoomer
software (Hamamatsu).
Quantification of immunostaining. To quantify cell proliferation, immune infil-
trate, p53 and Laminin-α3 staining, images were analysed using open-source ICY
software plug-in Manual Counting and Spot Detector76. Positively stained cells for
CD45, CD3, CD68 and EdU were counted per area of tumour or per area of stroma
(at least 2 sections/tumour, 3–6 regions/section) (Supplementary Fig. 5b). The total
number of nuclei was quantified using DAPI staining. Laminin α3 expression
quantification was performed using CellProfiler.
Statistical analysis. All graphs and statistical calculations were generated using R
software (R version 3.5.1) and Prism8 (GraphPad) software. Statistical significance
was computed with the test indicated in each figure legend. The number of animals
analysed in each group is indicated in each figure.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data from mouse TSCC whole-exome sequencing have been accessioned in the
European Nucleotide Archive (ENA) under the study accession number PRJEB32924
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(https://www.ebi.ac.uk/ena/browser/view/PRJEB32924). The detailed information of
lesion grading and matched samples is listed in Supplementary Data 1. Publicly available
databases or resources used in this research are as follows: COSMIC (http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic/) and Gene Ontology (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE54246)23. The datasets used to analyse recurrent
mutated genes in human TSCCs are listed in Supplementary Data 4 (https://www.ebi.ac.
uk/ega/studies/EGAS00001001329)34. All other remaining data are available within the
Article and Supplementary Files and or available from the authors upon request. A
reporting summary for this article is available as a Supplementary Information file.
Code availability
All relevant codes are available from the cited references or available from the authors
upon request. Custom code was generated using R to analyse the data and to generate the
plots. Code used in this article comprises: (i) CaVEMan, (ii) custom code for filtering
variants, (iii) cpg-pindel pipeline (v0.2.4w) for indel detection, (iv) MutationalPattern
script, (v) dndscv script, (vi) neutrality test script, (vii) custom code for data
manipulation and visualisation).
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